Clinical trials: Heart Septal Defects
ASD2(Secundum Atrial Septal Defect)
Outcomes of Transcatheter ASD Closure Guided by 3D-TEE
Atrial Septal Defect (ASD) is a common cardiac diagnosis among adults.Three-dimensional transesophageal echocardiography (3D-TEE) improve the visualization of ASD, its rims and surrounding structures and can be used for guidance…
- Trial name
- NCT03867708
- Testing
- ASD device closure
- Sponsor
- Assiut University
Heart Defects, Congenital
Transcatheter Versus Surgical Closure of Ventricular Septal Defect: A Comparative Study
The aim of this study is to compare Safety, efiicacy and clinical effects of surgical versus transcatheter closure of ventricular septal defect (VSD ).
- Trial name
- NCT05306483
- Testing
- Ventricular septal defect closure surgery, Ventricular septal defect closure catheter
- Where
- Egypt
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Intracardiac and Septal Defects, Valve and Anulus Repair
Prospective and Non-randomized Registry of CardioCel 3D
Post-market, prospective, multi-centre, open-label, registry designed to collect prospective safety and performance data on the use of CardioCel in patients with cardiovascular disorders and in accordance with local standard of…
- Conditions
- Intracardiac and Septal Defects, Valve and Anulus Repair, Great Vessel Reconstruction, Peripheral Vessel Reconstruction
- Trial name
- NCT04175327
- Testing
- CardioCel implantation
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- LeMaitre Vascular
Septal Defect, Atrial
Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
The primary objective of the GORE® Septal Occluder Study is to evaluate the safety and efficacy of the occluder device in the treatment of transcatheter closure of ostium secundum atrial septal defects (ASDs).
- Trial name
- NCT01711983
- Testing
- GORE® CARDIOFORM Septal Occluder
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- W.L.Gore & Associates
Patent Foramen Ovale, Stroke
PFO ACCESS Registry
Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.
- Trial name
- NCT00583401
- Testing
- Device closure with the AMPLATZER PFO Occluder
- Sponsor
- Abbott Medical Devices
Atrial Septal Defects
Safety and Effectiveness Study of the Solysafe Septal Occluder
Prospective mono-center clinical study to evaluate the safety and effectiveness of an intracardiac septal closure device in patients with atrial septum defect (ASD)
- Trial name
- NCT00353509
- Testing
- Device Closure of a Septal Defect
- Where
- Serbia
- Sponsor
- Carag AG
Congenital Heart Disease, Coarctation of Aorta
An Integrated Prenatal and Postnatal Treatment Model for the Treatment of Newborns With Critical Congenital Heart Disease
The purpose of this two-way cohort study was to explore whether an integrated prenatal and postnatal treatment model for neonates with critical congenital heart disease (CCHD) could be effective in avoiding preoperative…
- Conditions
- Congenital Heart Disease, Coarctation of Aorta, Aortic Stenosis, Pulmonary Atresia
- Trial name
- NCT06768008
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Anzhen Hospital
Ventricular Septal Defect
Cera™ VSD Occluder Post Market Clinical Follow-up
The objective of this post-market registry is to assess the safety and performance of the Lifetech Cera™ VSD occluder in a real-world and on-label fashion.
- Trial name
- NCT05939713
- Testing
- Cera™ VSD occluder implantation
- Where
- 8 sites in Taiwan
- Volunteers
- 152 people
- Sponsor
- Cardiac Children's Foundation Taiwan
Heart Septal Defects, Ventricular, Aortic Valve Insufficiency
Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect
The major risk factors of aortic valve replacement in three outlet types VSD after surgical repair were the severity of preoperative AR and older operation age.
- Trial name
- NCT00173186
- Where
- Taiwan
- Volunteers
- 411 people
- Sponsor
- National Taiwan University Hospital
Congenital Heart Defects, VSD
Bioabsorbable Occluder for Outlet VSD: Safety and Aortic Valve Effects
This study aims to evaluate the efficacy and safety of transcatheter bioabsorbable occluder closure in patients with outlet-type ventricular septal defect (outlet VSD), with a focus on assessing its impact on aortic valve…
- Trial name
- ABSORB-VSD (NCT07040579)
- Testing
- transcatheter closure of outlet VSDs with bioabsorbable occluders
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Heart Defects, Congenital
Study of Triostat in Infants During Heart Surgery
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery.
- Trial name
- NCT00027417
- Testing
- Liothyronine sodium/triiodothyronine, Cardiopulmonary bypass and cardiac surgery
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Michael Portman
Membranous Ventricular Septal Defects
Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER
The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.
- Trial name
- NCT00578708
- Testing
- AMPLATZER Membranous VSD Occluder
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Abbott Medical Devices
Atrial Septal Defects, Patent Ductus Arteriosus
Hyperion™ International Registry Trial
The purpose of this study is to determine the safety, performance and efficacy of the Hyperion™ Occluder Systems during treatment of ASD and PDA patients.
- Trial name
- COM-01 (NCT02220270)
- Testing
- ASD and PDA closure
- Where
- 10 sites in Algeria, China and 2 more
- Volunteers
- 200 people
- Sponsor
- European Cardiovascular Research Center
Congenital Disorders
Infant Weight Gain With Trisomy 21 and CAVC
Failure to thrive and difficulty gaining weight is a sign of uncompensated congestive heart failure (CHF). Infants with Trisomy 21 and complete atrioventricular canal defects (CAVC) frequently develop uncompensated CHF and weight…
- Trial name
- NCT00327951
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Children's Healthcare of Atlanta
Heart Septal Defects, Ventricular
Study of Energy Expenditure in Infants With Ventricular Septal Defects
OBJECTIVES: I. Compare the total daily energy expenditure in infants with ventricular septal defects vs healthy control infants.
- Trial name
- NCT00006272
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Atrial Septal Defect, Secundum Type
Assessment of LV/RV S and SR Before and After Percutaneous Closure of ASDs
The effect of Atrial Septal Defect (ASD) closure by using larger devices on the improvement in biventricular function remains an area of active research.
- Trial name
- NCT04091919
- Testing
- 2D- Transthoracic Echocardiography (TTE)
- Where
- 2 sites in Egypt
- Volunteers
- 50 people
- Sponsor
- Ayman khairy Mohamed
Heart Septal Defect, Heart Septal Defects, Atrial
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect
- Conditions
- Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities
- Trial name
- ASCENT ASD (NCT04591392)
- Testing
- reSept ASD Occluder
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 250 people
- Sponsor
- atHeart Medical
Tetralogy of Fallot
Follow up of Post-repair Tetralogy of Fallot
Tetralogy of Fallot is the most frequent complex congenital heart malformation. Over the past five decades, surgical repair has been performed with respectable results. However, relevant postoperative residues frequently remain.
- Trial name
- NCT00266188
- Where
- 14 sites in Germany
- Volunteers
- 406 people
- Sponsor
- Competence Network for Congenital Heart Defects
Ventricular Septal Defects
Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
The AMPLATZER Muscular VSD Occluder was approved by the US Food and Drug Administration (FDA) in September, 2007. This study is designed to further evaluate the safety and effectiveness in subjects implanted with the AMPLATZER…
- Trial name
- VPA (NCT00647387)
- Testing
- Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
- Where
- 51 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- Abbott Medical Devices
Congenital Heart Disease, Thiamine Deficiency
The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease
Currently, research on the effect of thiamine administration during transcatheter closure on the structure and function of the left ventricle by examining levels of matrix metalloproteinase-9 and tissue inhibitor of…
- Conditions
- Congenital Heart Disease, Thiamine Deficiency, Patent Ductus Arteriosus, Ventricular Septal Defect
- Trial name
- NCT06298344
- Testing
- Thiamine
- Where
- Indonesia
- Volunteers
- 86 people
- Sponsor
- Universitas Sumatera Utara